Studies also suggest it supports longer-term use compared to phentermine, which has a limited treatment duration
Levels or activity of DIP-related pathways may be altered during periods of chronic stress, sleep disruption, aging, or neurological imbalance
Semaglutide, a leading GLP-1 receptor agonist, demonstrated a mean weight loss of 14.9% at weekly doses of 2.4 mg, compared with only 2.4% for placebo
Why Retatrutide Could Change the Next Phase of Obesity Medicine The excitement around retatrutide is not just about weight loss
doi:10.1016/j.survophthal.2021.02.003 10
Some patients may experience changes in skin texture or looseness related to rapid weight lossa common outcome of GLP-1 receptor agonist therapywhich should not be confused with allergic drug reactions